25 XP   0   0   10

ATAI Life Sciences BV
Buy, Hold or Sell?

Let's analyse Atai together

PenkeI guess you are interested in ATAI Life Sciences BV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ATAI Life Sciences BV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about ATAI Life Sciences BV

I send you an email if I find something interesting about ATAI Life Sciences BV.

Quick analysis of Atai (30 sec.)










What can you expect buying and holding a share of Atai? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.51
Expected worth in 1 year
$1.24
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-0.27
Return On Investment
-15.2%

For what price can you sell your share?

Current Price per Share
$1.79
Expected price per share
$1.43 - $2.34
How sure are you?
50%

1. Valuation of Atai (5 min.)




Live pricePrice per Share (EOD)

$1.79

2. Growth of Atai (5 min.)




Is Atai growing?

Current yearPrevious yearGrowGrow %
How rich?$268.5m$244.9m-$121.6m-98.7%

How much money is Atai making?

Current yearPrevious yearGrowGrow %
Making money-$16.8m-$46.2m$29.3m174.3%
Net Profit Margin-44,420.8%-48,853.5%--

How much money comes from the company's main activities?

3. Financial Health of Atai (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#197 / 1031

Most Revenue
#635 / 1031

Most Profit
#692 / 1031

Most Efficient
#1002 / 1031

What can you expect buying and holding a share of Atai? (5 min.)

Welcome investor! Atai's management wants to use your money to grow the business. In return you get a share of Atai.

What can you expect buying and holding a share of Atai?

First you should know what it really means to hold a share of Atai. And how you can make/lose money.

Speculation

The Price per Share of Atai is $1.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atai.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atai, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.51. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atai.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.2513.9%-0.11-5.9%-0.30-16.5%-0.22-12.1%-0.22-12.1%
Usd Book Value Change Per Share0.2111.9%-0.07-3.8%-0.25-14.0%0.137.0%0.137.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.2111.9%-0.07-3.8%-0.25-14.0%0.137.0%0.137.0%
Usd Price Per Share1.29-1.87-4.92-5.04-5.04-
Price to Earnings Ratio1.29--1.40--4.37--4.88--4.88-
Price-to-Total Gains Ratio6.05--60.56--10.21--38.56--38.56-
Price to Book Ratio0.85-42.20-36.52-27.21-27.21-
Price-to-Total Gains Ratio6.05--60.56--10.21--38.56--38.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.79
Number of shares558
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.070.13
Usd Total Gains Per Share-0.070.13
Gains per Quarter (558 shares)-37.8570.32
Gains per Year (558 shares)-151.40281.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-151-1610281271
20-303-3120563552
30-454-4630844833
40-606-614011251114
50-757-765014061395
60-908-916016881676
70-1060-1067019691957
80-1211-1218022502238
90-1363-1369025312519
100-1514-1520028132800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%6.06.00.050.0%6.06.00.050.0%6.06.00.050.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%6.06.00.050.0%6.06.00.050.0%6.06.00.050.0%

Fundamentals of Atai

About ATAI Life Sciences BV

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Fundamental data was last updated by Penke on 2024-03-20 10:30:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of ATAI Life Sciences BV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Atai earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atai to the Biotechnology industry mean.
  • A Net Profit Margin of 50,855.2% means that $508.55 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ATAI Life Sciences BV:

  • The MRQ is 50,855.2%. The company is making a huge profit. +2
  • The TTM is -44,420.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ50,855.2%TTM-44,420.8%+95,275.9%
TTM-44,420.8%YOY-48,853.5%+4,432.8%
TTM-44,420.8%5Y-32,067.3%-12,353.5%
5Y-32,067.3%10Y-32,067.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ50,855.2%-171.8%+51,027.0%
TTM-44,420.8%-205.8%-44,215.0%
YOY-48,853.5%-262.1%-48,591.4%
5Y-32,067.3%-455.6%-31,611.7%
10Y-32,067.3%-589.0%-31,478.3%
1.1.2. Return on Assets

Shows how efficient Atai is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atai to the Biotechnology industry mean.
  • 14.4% Return on Assets means that Atai generated $0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ATAI Life Sciences BV:

  • The MRQ is 14.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -6.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ14.4%TTM-6.3%+20.7%
TTM-6.3%YOY-12.1%+5.7%
TTM-6.3%5Y-13.9%+7.6%
5Y-13.9%10Y-13.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.4%-12.5%+26.9%
TTM-6.3%-12.2%+5.9%
YOY-12.1%-11.2%-0.9%
5Y-13.9%-13.4%-0.5%
10Y-13.9%-14.7%+0.8%
1.1.3. Return on Equity

Shows how efficient Atai is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atai to the Biotechnology industry mean.
  • 16.6% Return on Equity means Atai generated $0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ATAI Life Sciences BV:

  • The MRQ is 16.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ16.6%TTM-4.1%+20.7%
TTM-4.1%YOY-13.6%+9.5%
TTM-4.1%5Y-15.2%+11.1%
5Y-15.2%10Y-15.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.6%-15.8%+32.4%
TTM-4.1%-15.7%+11.6%
YOY-13.6%-13.9%+0.3%
5Y-15.2%-18.3%+3.1%
10Y-15.2%-19.2%+4.0%

1.2. Operating Efficiency of ATAI Life Sciences BV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Atai is operating .

  • Measures how much profit Atai makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atai to the Biotechnology industry mean.
  • An Operating Margin of -30,928.7% means the company generated $-309.29  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ATAI Life Sciences BV:

  • The MRQ is -30,928.7%. The company is operating very inefficient. -2
  • The TTM is -59,105.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-30,928.7%TTM-59,105.9%+28,177.2%
TTM-59,105.9%YOY-50,137.0%-8,968.9%
TTM-59,105.9%5Y-37,673.2%-21,432.6%
5Y-37,673.2%10Y-37,673.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30,928.7%-299.1%-30,629.6%
TTM-59,105.9%-210.1%-58,895.8%
YOY-50,137.0%-279.7%-49,857.3%
5Y-37,673.2%-459.9%-37,213.3%
10Y-37,673.2%-596.9%-37,076.3%
1.2.2. Operating Ratio

Measures how efficient Atai is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 310.29 means that the operating costs are $310.29 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ATAI Life Sciences BV:

  • The MRQ is 310.287. The company is inefficient in keeping operating costs low. -1
  • The TTM is 597.950. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ310.287TTM597.950-287.663
TTM597.950YOY501.938+96.012
TTM597.9505Y377.227+220.724
5Y377.22710Y377.2270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ310.2872.861+307.426
TTM597.9503.193+594.757
YOY501.9383.615+498.323
5Y377.2275.560+371.667
10Y377.2277.396+369.831

1.3. Liquidity of ATAI Life Sciences BV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Atai is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.04 means the company has $11.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ATAI Life Sciences BV:

  • The MRQ is 11.035. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.962. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.035TTM12.962-1.926
TTM12.962YOY15.174-2.212
TTM12.9625Y15.718-2.757
5Y15.71810Y15.7180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.0353.986+7.049
TTM12.9624.440+8.522
YOY15.1745.552+9.622
5Y15.7186.158+9.560
10Y15.7186.492+9.226
1.3.2. Quick Ratio

Measures if Atai is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atai to the Biotechnology industry mean.
  • A Quick Ratio of 17.42 means the company can pay off $17.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ATAI Life Sciences BV:

  • The MRQ is 17.416. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.262. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.416TTM17.262+0.154
TTM17.262YOY21.363-4.101
TTM17.2625Y19.255-1.992
5Y19.25510Y19.2550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.4163.638+13.778
TTM17.2624.168+13.094
YOY21.3635.515+15.848
5Y19.2556.012+13.243
10Y19.2556.209+13.046

1.4. Solvency of ATAI Life Sciences BV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Atai assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atai to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Atai assets are financed with 12.9% credit (debt) and the remaining percentage (100% - 12.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ATAI Life Sciences BV:

  • The MRQ is 0.129. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.562. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.129TTM0.562-0.433
TTM0.562YOY0.318+0.244
TTM0.5625Y0.327+0.235
5Y0.32710Y0.3270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1290.335-0.206
TTM0.5620.330+0.232
YOY0.3180.267+0.051
5Y0.3270.367-0.040
10Y0.3270.378-0.051
1.4.2. Debt to Equity Ratio

Measures if Atai is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atai to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.9% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ATAI Life Sciences BV:

  • The MRQ is 0.149. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.370. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.149TTM0.370-0.221
TTM0.370YOY0.353+0.017
TTM0.3705Y0.282+0.088
5Y0.28210Y0.2820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1490.376-0.227
TTM0.3700.398-0.028
YOY0.3530.334+0.019
5Y0.2820.429-0.147
10Y0.2820.476-0.194

2. Market Valuation of ATAI Life Sciences BV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atai generates.

  • Above 15 is considered overpriced but always compare Atai to the Biotechnology industry mean.
  • A PE ratio of 1.29 means the investor is paying $1.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ATAI Life Sciences BV:

  • The EOD is 1.796. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.294. Based on the earnings, the company is cheap. +2
  • The TTM is -1.396. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.796MRQ1.294+0.502
MRQ1.294TTM-1.396+2.691
TTM-1.396YOY-4.368+2.972
TTM-1.3965Y-4.883+3.487
5Y-4.88310Y-4.8830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.796-2.643+4.439
MRQ1.294-2.418+3.712
TTM-1.396-2.742+1.346
YOY-4.368-4.123-0.245
5Y-4.883-6.257+1.374
10Y-4.883-6.478+1.595
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ATAI Life Sciences BV:

  • The EOD is -4.311. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.107. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.331. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.311MRQ-3.107-1.204
MRQ-3.107TTM-3.331+0.224
TTM-3.331YOY-8.898+5.567
TTM-3.3315Y33.644-36.975
5Y33.64410Y33.6440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.311-3.244-1.067
MRQ-3.107-2.939-0.168
TTM-3.331-3.478+0.147
YOY-8.898-5.592-3.306
5Y33.644-8.473+42.117
10Y33.644-8.881+42.525
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Atai is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.85 means the investor is paying $0.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ATAI Life Sciences BV:

  • The EOD is 1.184. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.853. Based on the equity, the company is cheap. +2
  • The TTM is 42.200. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.184MRQ0.853+0.331
MRQ0.853TTM42.200-41.347
TTM42.200YOY36.519+5.681
TTM42.2005Y27.210+14.990
5Y27.21010Y27.2100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1842.124-0.940
MRQ0.8532.041-1.188
TTM42.2002.118+40.082
YOY36.5192.915+33.604
5Y27.2103.682+23.528
10Y27.2104.114+23.096
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ATAI Life Sciences BV.

3.1. Institutions holding ATAI Life Sciences BV

Institutions are holding 28.02% of the shares of ATAI Life Sciences BV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Morgan Stanley - Brokerage Accounts1.89540.0004314658160268723.6915
2023-12-31BlackRock Inc0.81930.00011360204-1103839-44.7979
2023-12-31Marshall Wace Asset Management Ltd0.46740.00197758897758890
2023-12-31Millennium Management LLC0.45830.0005760756667056711.9061
2023-12-31Brown University0.43280.365971850000
2023-12-31Mirae Asset Global Investments (Korea) Co Ltd0.37570.0018623677-8033-1.2716
2023-12-31Bank of America Corp0.33650.0001558637232224.3372
2023-12-31Two Sigma Investments LLC0.25040.001441574313031445.6555
2023-12-31Vanguard Group Inc0.24660409462-113729-21.7376
2023-12-31Franklin Resources Inc0.21470.000235635700
2023-12-31JPMorgan Chase & Co0.19160318014178135127.3494
2023-12-31Cresset Asset Management, LLC0.18770.002631161300
2023-12-31Tejara Capital Ltd0.17480.171429021500
2023-12-31Barclays PLC0.1480.0001245717-22923-8.533
2023-12-31Goldman Sachs Group Inc0.13450223288166646294.2092
2023-12-31AdvisorShares Investments, LLC0.1180.0647195869173469.7164
2023-12-31Hyperion Capital Advisors LP0.10140.128316841600
2023-12-31Susquehanna International Group, LLP0.08960148813126358562.7165
2023-12-31HRT FINANCIAL LLC0.07880.00131308491308490
2023-12-31Qube Research & Technologies0.07740.0004128494101204370.8465
Total 6.79890.741111287094+1671182+14.8%

3.2. Funds holding ATAI Life Sciences BV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Biotechnology ETF0.52980.0224879505-3960-0.4482
2024-01-31Horizons Psychedelic Stock ETF0.363212.7699602976-16556-2.6723
2023-12-31Morgan Stanley Inst Inception I0.34360.175157033000
2023-12-31Morgan Stanley Inception0.34360.176657033000
2024-01-31Vanguard Health Care ETF0.24840.003741243229700.7253
2024-02-29iShares Healthcare Innov ETF USD Acc0.19570.055232483700
2024-01-31EQ/Morgan Stanley Small Cap Growth K0.16330.132527103400
2024-02-29AdvisorShares Psychedelics ETF0.10564.979917536300
2024-01-31Fidelity Nasdaq Composite Index0.07060.001411722600
2024-02-29iShares Ageing Population ETF USD Acc0.06680.03811097200
2024-02-29iShares Nasdaq US Biotech ETF USD Acc0.05920.03839832216551.7121
2024-02-29SPDR® S&P International Small Cap ETF0.02540.01324216000
2023-09-30Sygnia Itrix 4th IR Global Equity ETF0.02490.05364134800
2023-10-31NT Wld Sm Cap ESG Low Carb IdxFdrBGBPAcc0.01640.002627278272780
2024-02-29Avantis US Small Cap Equity ETF0.01360.00572264400
2023-06-30Sygnia 4th Industrial Revolution Gl Eq B0.01270.020921075825364.3659
2023-07-10Daiwa Moonshot Index Mother Fund0.01260.982720847208470
2023-09-30Undrly L&G Pen PMC Multi Asset0.01110.000118479184790
2024-02-29ProShares Ultra Nasdaq Biotechnology0.00750.025612403-501-3.8825
2023-12-31L&G Global Small Cap Eq Idx C GBP Acc0.00650.000410846-43385-80.0004
Total 2.620519.49784350407+15080+0.3%

3.3. Insider Transactions

Insiders are holding 10.045% of the shares of ATAI Life Sciences BV.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-16Florian BrandBUY200001.16
2023-09-13Florian BrandBUY400001.45
2023-03-29Apeiron Investment Group Ltd.BUY12142971.32
2023-03-29Florian BrandBUY700001.48

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ATAI Life Sciences BV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.213-0.068+132%-0.251+218%0.126+69%0.126+69%
Book Value Per Share--1.5120.716+111%1.475+3%1.314+15%1.314+15%
Current Ratio--11.03512.962-15%15.174-27%15.718-30%15.718-30%
Debt To Asset Ratio--0.1290.562-77%0.318-60%0.327-61%0.327-61%
Debt To Equity Ratio--0.1490.370-60%0.353-58%0.282-47%0.282-47%
Dividend Per Share----0%-0%-0%-0%
Eps--0.249-0.105+142%-0.296+219%-0.217+187%-0.217+187%
Free Cash Flow Per Share---0.104-0.139+34%-0.144+39%-0.119+15%-0.119+15%
Free Cash Flow To Equity Per Share---0.104-0.140+35%-0.109+5%0.138-175%0.138-175%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap297157900.000+23%229060105.170314165501.293-27%816354175.000-72%837379300.431-73%837379300.431-73%
Net Profit Margin--508.552-444.208+187%-488.535+196%-320.673+163%-320.673+163%
Operating Margin---309.287-591.059+91%-501.370+62%-376.732+22%-376.732+22%
Operating Ratio--310.287597.950-48%501.938-38%377.227-18%377.227-18%
Pb Ratio1.184+28%0.85342.200-98%36.519-98%27.210-97%27.210-97%
Pe Ratio1.796+28%1.294-1.396+208%-4.368+437%-4.883+477%-4.883+477%
Price Per Share1.790+28%1.2901.870-31%4.918-74%5.037-74%5.037-74%
Price To Free Cash Flow Ratio-4.311-39%-3.107-3.331+7%-8.898+186%33.644-109%33.644-109%
Price To Total Gains Ratio8.394+28%6.049-60.561+1101%-10.213+269%-38.560+737%-38.560+737%
Quick Ratio--17.41617.262+1%21.363-18%19.255-10%19.255-10%
Return On Assets--0.144-0.063+144%-0.121+184%-0.139+197%-0.139+197%
Return On Equity--0.166-0.041+125%-0.136+182%-0.152+191%-0.152+191%
Total Gains Per Share--0.213-0.068+132%-0.251+218%0.126+69%0.126+69%
Usd Book Value--268512000.000123247500.000+118%244902500.000+10%219634666.667+22%219634666.667+22%
Usd Book Value Change Per Share--0.213-0.068+132%-0.251+218%0.126+69%0.126+69%
Usd Book Value Per Share--1.5120.716+111%1.475+3%1.314+15%1.314+15%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.249-0.105+142%-0.296+219%-0.217+187%-0.217+187%
Usd Free Cash Flow---18433000.000-23364250.000+27%-23907250.000+30%-19904833.333+8%-19904833.333+8%
Usd Free Cash Flow Per Share---0.104-0.139+34%-0.144+39%-0.119+15%-0.119+15%
Usd Free Cash Flow To Equity Per Share---0.104-0.140+35%-0.109+5%0.138-175%0.138-175%
Usd Market Cap297157900.000+23%229060105.170314165501.293-27%816354175.000-72%837379300.431-73%837379300.431-73%
Usd Price Per Share1.790+28%1.2901.870-31%4.918-74%5.037-74%5.037-74%
Usd Profit--44244000.000-16860500.000+138%-46241250.000+205%-34827666.667+179%-34827666.667+179%
Usd Revenue--87000.00083500.000+4%106000.000-18%1742000.000-95%1742000.000-95%
Usd Total Gains Per Share--0.213-0.068+132%-0.251+218%0.126+69%0.126+69%
 EOD+5 -3MRQTTM+27 -6YOY+25 -85Y+24 -910Y+24 -9

4.2. Fundamental Score

Let's check the fundamental score of ATAI Life Sciences BV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.796
Price to Book Ratio (EOD)Between0-11.184
Net Profit Margin (MRQ)Greater than0508.552
Operating Margin (MRQ)Greater than0-309.287
Quick Ratio (MRQ)Greater than117.416
Current Ratio (MRQ)Greater than111.035
Debt to Asset Ratio (MRQ)Less than10.129
Debt to Equity Ratio (MRQ)Less than10.149
Return on Equity (MRQ)Greater than0.150.166
Return on Assets (MRQ)Greater than0.050.144
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of ATAI Life Sciences BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.185
Ma 20Greater thanMa 501.860
Ma 50Greater thanMa 1001.833
Ma 100Greater thanMa 2001.591
OpenGreater thanClose1.800
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Income before Tax  -33,134-6,187-39,3216,165-33,1561,498-31,65875,50543,847
Minority Interest  -1,814176-1,638419-1,219490-7291,602873
Net Income  -33,269-12,054-45,32312,002-33,321279-33,04277,28644,244
Gross Profit  -12-3-15-115-130107-233613
Net Income from Continuing Operations  -33,269-12,054-45,32312,002-33,3211,478-31,84375,21443,371



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets308,220
Total Liabilities39,708
Total Stockholder Equity266,276
 As reported
Total Liabilities 39,708
Total Stockholder Equity+ 266,276
Total Assets = 308,220

Assets

Total Assets308,220
Total Current Assets217,344
Long-term Assets90,876
Total Current Assets
Cash And Cash Equivalents 76,492
Short-term Investments 132,502
Net Receivables 1,519
Other Current Assets 6,831
Total Current Assets  (as reported)217,344
Total Current Assets  (calculated)217,344
+/-0
Long-term Assets
Property Plant Equipment 2,250
Long Term Investments 75,170
Long-term Assets Other 13,456
Long-term Assets  (as reported)90,876
Long-term Assets  (calculated)90,876
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,695
Long-term Liabilities20,013
Total Stockholder Equity266,276
Total Current Liabilities
Short-term Debt 292
Accounts payable 5,506
Other Current Liabilities 889
Total Current Liabilities  (as reported)19,695
Total Current Liabilities  (calculated)6,687
+/- 13,008
Long-term Liabilities
Long term Debt 15,366
Capital Lease Obligations Min Short Term Debt1,011
Long-term Liabilities Other 3,636
Long-term Liabilities  (as reported)20,013
Long-term Liabilities  (calculated)20,013
+/-0
Total Stockholder Equity
Common Stock18,571
Retained Earnings -532,647
Accumulated Other Comprehensive Income -19,109
Other Stockholders Equity 799,461
Total Stockholder Equity (as reported)266,276
Total Stockholder Equity (calculated)266,276
+/-0
Other
Capital Stock18,571
Cash and Short Term Investments 208,994
Common Stock Shares Outstanding 177,566
Current Deferred Revenue13,008
Liabilities and Stockholders Equity 308,220
Net Debt -59,823
Net Invested Capital 281,642
Net Working Capital 197,649
Property Plant and Equipment Gross 2,250
Short Long Term Debt Total 16,669



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
111,548
145,261
505,961
484,109
414,166
383,732
348,936
342,597
305,441
280,717
253,595
308,220
308,220253,595280,717305,441342,597348,936383,732414,166484,109505,961145,261111,548000
   > Total Current Assets 
0
0
0
99,548
131,119
457,586
441,859
375,082
348,786
323,608
317,482
287,145
267,933
242,770
217,344
217,344242,770267,933287,145317,482323,608348,786375,082441,859457,586131,11999,548000
       Cash And Cash Equivalents 
0
0
0
97,246
104,369
453,622
430,308
362,266
123,975
84,132
142,539
190,613
185,885
141,090
76,492
76,492141,090185,885190,613142,53984,132123,975362,266430,308453,622104,36997,246000
       Short-term Investments 
0
0
0
0
0
19,780
0
0
210,939
228,354
161,518
82,496
63,998
86,402
132,502
132,50286,40263,99882,496161,518228,354210,9390019,78000000
       Net Receivables 
0
0
0
1,291
24,486
1,344
3,386
913
7,097
5,900
5,352
5,631
8,851
9,021
1,519
1,5199,0218,8515,6315,3525,9007,0979133,3861,34424,4861,291000
       Other Current Assets 
0
0
0
554
65
111
461
756
1,389
1,322
1,367
14,036
9,199
6,257
6,831
6,8316,2579,19914,0361,3671,3221,38975646111165554000
   > Long-term Assets 
0
0
0
12,000
14,142
48,375
42,250
39,084
34,946
25,328
25,115
18,296
12,784
10,825
90,876
90,87610,82512,78418,29625,11525,32834,94639,08442,25048,37514,14212,000000
       Property Plant Equipment 
0
0
0
71
140
331
138
149
178
303
728
928
2,603
2,410
2,250
2,2502,4102,60392872830317814913833114071000
       Long Term Investments 
0
0
0
8,044
7,112
42,773
40,850
27,759
27,264
17,435
15,649
14,017
7,001
5,148
75,170
75,1705,1487,00114,01715,64917,43527,26427,75940,85042,7737,1128,044000
       Other Assets 
0
0
0
0
6,890
5,271
5,954
11,176
14,432
14,630
15,889
10,613
0
4,424
0
04,424010,61315,88914,63014,43211,1765,9545,2716,8900000
> Total Liabilities 
0
0
0
16,180
25,268
21,066
21,349
405,115
29,375
28,814
46,517
300,415
276,902
37,958
39,708
39,70837,958276,902300,41546,51728,81429,375405,11521,34921,06625,26816,180000
   > Total Current Liabilities 
0
0
0
12,298
19,063
14,185
15,317
20,935
22,091
21,957
25,913
19,897
20,871
17,926
19,695
19,69517,92620,87119,89725,91321,95722,09120,93515,31714,18519,06312,298000
       Short-term Debt 
0
0
0
0
1,265
39
38
0
0
0
0
0
317
322
292
2923223170000038391,2650000
       Short Long Term Debt 
0
0
0
0
1,265
39
38
0
0
0
0
0
0
0
0
0000000038391,2650000
       Accounts payable 
0
0
0
3,083
7,031
6,202
1,974
6,004
3,612
2,738
3,511
2,399
4,915
3,859
5,506
5,5063,8594,9152,3993,5112,7383,6126,0041,9746,2027,0313,083000
       Other Current Liabilities 
0
0
0
9,215
10,647
7,824
13,125
14,931
18,479
19,219
22,402
17,498
15,639
890
889
88989015,63917,49822,40219,21918,47914,93113,1257,82410,6479,215000
   > Long-term Liabilities 
0
0
0
3,882
6,205
6,881
6,032
384,180
7,284
6,857
20,604
280,518
256,031
20,032
20,013
20,01320,032256,031280,51820,6046,8577,284384,1806,0326,8816,2053,882000
       Long term Debt Total 
0
0
0
0
0
1,176
800
0
725
619
15,001
14,702
14,783
14,868
0
014,86814,78314,70215,00161972508001,17600000
       Other Liabilities 
0
0
0
0
2,105
3,305
2,832
6,529
6,559
4,038
3,503
2,261
1,434
1,349
0
01,3491,4342,2613,5034,0386,5596,5292,8323,3052,1050000
       Deferred Long Term Liability 
0
0
0
0
4,218
0
0
0
0
0
0
0
0
0
0
00000000004,2180000
> Total Stockholder Equity
0
0
0
90,822
111,390
474,850
453,186
376,908
346,006
311,675
289,399
260,740
-546,101
212,550
266,276
266,276212,550-546,101260,740289,399311,675346,006376,908453,186474,850111,39090,822000
   Common Stock
0
0
0
13,372
15,253
17,299
17,870
18,002
18,007
18,114
18,554
18,562
18,571
18,571
18,571
18,57118,57118,57118,56218,55418,11418,00718,00217,87017,29915,25313,372000
   Retained Earnings Total Equity0-576,891-543,849-510,188-465,178-431,290-394,6720-268,926-237,76800000
   Accumulated Other Comprehensive Income 
0
0
0
5,819
1,977
3,937
-5,233
-8,336
-12,709
-21,191
-25,788
-21,702
-20,823
-20,818
-19,109
-19,109-20,818-20,823-21,702-25,788-21,191-12,709-8,336-5,2333,9371,9775,819000
   Capital Surplus 
0
0
0
0
0
691,382
709,475
0
735,380
746,042
761,811
774,092
782,926
791,688
0
0791,688782,926774,092761,811746,042735,3800709,475691,38200000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
0
261,626
283,467
691,382
709,475
725,045
735,380
746,042
761,811
774,068
546,101
791,688
799,461
799,461791,688546,101774,068761,811746,042735,380725,045709,475691,382283,467261,626000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue334
Cost of Revenue--
Gross Profit-334
 
Operating Income (+$)
Gross Profit-
Operating Expense-129,809
Operating Income-129,475-129,809
 
Operating Expense (+$)
Research Development69,923
Selling General Administrative59,886
Selling And Marketing Expenses-
Operating Expense129,809129,809
 
Net Interest Income (+$)
Interest Income1,378
Interest Expense--
Other Finance Cost-1,965
Net Interest Income-587
 
Pretax Income (+$)
Operating Income-129,475
Net Interest Income-587
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-60,287-199,250
EBIT - interestExpense = 0
-66,943
-66,943
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--60,287
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-60,287
Tax Provision-6,590
Net Income From Continuing Ops-71,402-66,877
Net Income-66,943
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net69,775587
 

Technical Analysis of Atai
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Atai. The general trend of Atai is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Atai's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ATAI Life Sciences BV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.23 < 2.315 < 2.34.

The bearish price targets are: 1.58 > 1.56 > 1.43.

Tweet this
ATAI Life Sciences BV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ATAI Life Sciences BV. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ATAI Life Sciences BV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ATAI Life Sciences BV. The current macd is -0.04856914.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Atai price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Atai. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Atai price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ATAI Life Sciences BV Daily Moving Average Convergence/Divergence (MACD) ChartATAI Life Sciences BV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ATAI Life Sciences BV. The current adx is 24.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Atai shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
ATAI Life Sciences BV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ATAI Life Sciences BV. The current sar is 1.8980271.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ATAI Life Sciences BV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ATAI Life Sciences BV. The current rsi is 49.18. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
ATAI Life Sciences BV Daily Relative Strength Index (RSI) ChartATAI Life Sciences BV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ATAI Life Sciences BV. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Atai price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
ATAI Life Sciences BV Daily Stochastic Oscillator ChartATAI Life Sciences BV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ATAI Life Sciences BV. The current cci is -39.63930842.

ATAI Life Sciences BV Daily Commodity Channel Index (CCI) ChartATAI Life Sciences BV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ATAI Life Sciences BV. The current cmo is 1.69727839.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
ATAI Life Sciences BV Daily Chande Momentum Oscillator (CMO) ChartATAI Life Sciences BV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ATAI Life Sciences BV. The current willr is -71.42857143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Atai is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
ATAI Life Sciences BV Daily Williams %R ChartATAI Life Sciences BV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ATAI Life Sciences BV.

ATAI Life Sciences BV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ATAI Life Sciences BV. The current atr is 0.14245173.

ATAI Life Sciences BV Daily Average True Range (ATR) ChartATAI Life Sciences BV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ATAI Life Sciences BV. The current obv is -24,969,559.

ATAI Life Sciences BV Daily On-Balance Volume (OBV) ChartATAI Life Sciences BV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ATAI Life Sciences BV. The current mfi is 37.16.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ATAI Life Sciences BV Daily Money Flow Index (MFI) ChartATAI Life Sciences BV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ATAI Life Sciences BV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

ATAI Life Sciences BV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ATAI Life Sciences BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.185
Ma 20Greater thanMa 501.860
Ma 50Greater thanMa 1001.833
Ma 100Greater thanMa 2001.591
OpenGreater thanClose1.800
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Atai with someone you think should read this too:
  • Are you bullish or bearish on Atai? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Atai? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ATAI Life Sciences BV

I send you an email if I find something interesting about ATAI Life Sciences BV.


Comments

How you think about this?

Leave a comment

Stay informed about ATAI Life Sciences BV.

Receive notifications about ATAI Life Sciences BV in your mailbox!